Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

Crinò, L., Scagliotti, G. V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., Sassi, M., Barni, S., Ravaioli, A., Adamo, V., Portalone, L., Cruciani, G., Masotti, A., Ferrara, G., Gozzelino, F., Tonato, M.·1999·Journal of Clinical Oncology

Abstract

PURPOSE: To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) chemotherapy in patients with stage IIIB (limited to T4 for pleural effusion and N3 for supraclavicular lymph nodes) or stage IV non–small-cell lung cancer (NSCLC). The end points were the evaluation of quality of life (QoL), response rates, survival, and toxicity. PATIENTS AND METHODS: Three hundred seven patients were randomized to receive either gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 plus cisplatin 100 mg/m 2 on day 2, every 28 days, or mitomycin 6 mg/m 2, ifosfamide 3,000 mg/m 2, and mesna on day 1 plus cisplatin 100 mg/m 2 on day 2, every 28 days. The whole-blood cell count was repeated on day 1 in both arms and weekly in the GC arm before each gemcitabine administration. RESULTS: No major differences in changes in QoL were observed between the two treatment arms. The objective response rate was 38% in the GC arm compared with 26% in the MIC arm (P = .029). The median survival time was 8.6 months in the GC arm and 9.6 months in the MIC arm (P = .877, log-rank test). Grade 3 and 4 thrombocytopenia was significantly worse in the GC arm (64% v 28%, P < .001), whereas grade 3 and 4 alopecia was reported more commonly in the MIC arm (39% v 12%, P < .001). CONCLUSION: We report an increased response rate without changes in QoL and a similar overall survival, time to progression, and time to treatment failure for the GC when compared with the MIC regimen in the treatment of advanced NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1999.17.11.3522

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 362

Metadata

Authors
Crinò, L., Scagliotti, G. V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., Sassi, M., Barni, S., Ravaioli, A., Adamo, V., Portalone, L., Cruciani, G., Masotti, A., Ferrara, G., Gozzelino, F., & Tonato, M.
Venue
Journal of Clinical Oncology
Published
1999-11
Volume
17
Issue
11
Pages
3522-3530
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1961110209
Cited by
362
References
17
FWCI
31.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project. https://app.cochat.ai/papers/10.1200/jco.1999.17.11.3522
The paper
Crinò, L., Scagliotti, G. V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., Sassi, M., Barni, S., Ravaioli, A., Adamo, V., Portalone, L., Cruciani, G., Masotti, A., Ferrara, G., Gozzelino, F., & Tonato, M. (1999). Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.11.3522

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.